Brainsway Ltd.
BrainsWay develops and provides Deep Transcranial Magnetic Stimulation (Deep TMS) systems for noninvasive treatment of mental health disorders. Its customers are principally doctors, hospitals and medical centers in psychiatry. The system uses proprietary H-Coil helmets to deliver magnetic pulses, and includes a stimulator, user interface, positioning devices and cooling system. Cleared indications include major depressive disorder, obsessive-compulsive disorder and smoking addiction. BrainsWay also has CE Mark for various psychiatric and neurological indications. BrainsWay makes money through sales and leases of its Deep TMS systems, as well as related and other services. It offers flexible pricing models and sells and leases systems to treatment providers. Its principal executive offices are in Jerusalem, Israel, and it also has U.S. offices in Boston.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $BWAY in the last 30 days.
See all $BWAY insider activity →Brainsway (BWAY) reported Q3 EPS of $0.05, missing estimates by $0.04, but revenue of $18.1M exceeded expectations. The stock is down 28.68% over 3 months but up 53.36% year-over-year. InvestingPro rates its financial health as 'great performance'.
Brainsway Ltd. (BWAY) furnished an SEC Form 6-K — earnings release. EXHIBIT 99.1 BrainsWay Reports Third Quarter 2026 Financial Results and Operational Highlights Revenue increased 3 4 % to $18. 1 million in Q3 2026 ; Operating income rose 107 % to $2. 6 million and Adjusted EBITDA rose approximately 92 % to $ 3 . 9 million Remaining performance
H.C. Wainwright reiterated a Buy rating and $19.00 price target for Brainsway (BWAY), citing a 71% upside potential. The company announced a strategic collaboration with Mindful Health Solutions to expand access to mental health treatments. Brainsway reported Q2 2026 revenue of $17.1 million, exceeding estimates, and raised its full-year revenue outlook to $68-$70 million. The stock has shown 32% revenue growth and a 75% gross profit margin over the last year.
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning BWAY (Brainsway Ltd.). Coverage has skewed bullish: 2 bullish, 2 neutral, and 1 bearish.
Recent BWAY coverage spans financial news, earnings and regulation.
Earnings miss may pressure the stock lower.
Earnings beat and updated guidance
Collaboration is expected to boost revenue growth and market adoption of Brainsway's neurostimulation devices.
The partnership could broaden BrainsWay's market reach and drive incremental revenue, but no immediate financial terms were disclosed.
Analyst upgrade with higher target supports upside potential.
AlphAI scores every news story that mentions BWAY with an AI model for sentiment and relevance, and aggregates insider trades from Brainsway Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Brainsway (BWAY) reported Q3 EPS of $0.05, missing estimates by $0.04, but revenue of $18.1M exceeded expectations. The stock is down 28.68% over 3 months but up 53.36% year-over-year. InvestingPro rates its financial health as 'great performance'.
Brainsway Ltd. (BWAY) furnished an SEC Form 6-K — earnings release. EXHIBIT 99.1 BrainsWay Reports Third Quarter 2026 Financial Results and Operational Highlights Revenue increased 3 4 % to $18. 1 million in Q3 2026 ; Operating income rose 107 % to $2. 6 million and Adjusted EBITDA rose approximately 92 % to $ 3 . 9 million Remaining performance
H.C. Wainwright reiterated a Buy rating and $19.00 price target for Brainsway (BWAY), citing a 71% upside potential. The company announced a strategic collaboration with Mindful Health Solutions to expand access to mental health treatments. Brainsway reported Q2 2026 revenue of $17.1 million, exceeding estimates, and raised its full-year revenue outlook to $68-$70 million. The stock has shown 32% revenue growth and a 75% gross profit margin over the last year.
BrainsWay Ltd. (BWAY) partnered with Mindful Health Solutions, a behavioral health provider, to expand access to its Deep TMS and SWIFT treatments. The collaboration includes education initiatives and research. BrainsWay also invested $0.8M in Heading Health's management services organization. The company develops neuromodulation therapies for mental health disorders, with FDA clearance for three indications.
H.C. Wainwright maintained a Buy rating and $19 price target for Brainsway (BWAY), citing expanded insurance coverage for its Deep TMS treatment. The stock trades at $11.93, with a P/E of 52 and PEG of 0.44. Brainsway reported Q2 2026 revenue of $17.1M, exceeding estimates, and raised its full-year outlook. The company also partnered with Inland Psychiatric Medical Group.
BrainsWay Ltd. (BWAY) announced that U.S. insurance policies covering its Deep TMS for OCD now reach over 118 million lives, indicating broader access and ongoing reimbursement momentum.
H.C. Wainwright reiterated a Buy rating and $19.00 price target on Brainsway (BWAY) following its partnership with Inland Psychiatric Medical Group. The stock has a 68% upside potential from its current price of $11.99. Brainsway reported Q2 2026 revenue of $17.1M, beating estimates, and raised its full-year revenue guidance to $68M-$70M, citing strong demand for its Deep TMS systems.
BrainsWay Ltd. (NASDAQ: BWAY) announced a strategic collaboration with Inland Psychiatric Medical Group (IPMG) to install Deep TMS systems and explore clinical research projects. BrainsWay's Deep TMS is FDA-cleared for treating major depressive disorder, OCD, and smoking addiction. The partnership aims to advance interventional psychiatry and mental health care in Southern California.
Bumble (BMBL) surged 56.7% to $5.96 after agreeing to a $6.05/share private takeover by Ithaca Holdings. Other movers: Fermi (FRMI) +22.5%, Enerflex (EFXT) +13.6%, BigBear.ai (BBAI) +9.1%, MongoDB (MDB) +6.8%, Xtend AI (XTND) +6.6%.
BrainsWay Ltd. (BWAY) reports that its SWIFT Accelerated Deep TMS protocol is now covered by U.S. medical policies for over 70 million lives, indicating growing payer acceptance. The company attributes this to favorable policy momentum for Deep TMS in treating MDD and OCD, following prior FDA clearances.
